末梢神経障害の世界市場レポート 2025年

末梢神経障害市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR12.9％で75億2,000万米ドルに成長します。予測期間の成長は、慢性疾患、特に糖尿病やがんの有病率の継続的な上昇、神経障害性疼痛経路を標的とした薬理療法の進歩、革新的な治療法の研究開発への投資の増加、神経障害性症状の遠隔モニタリングと個別化管理のためのデジタルヘルスソリューションの統合、患者中心のケアモデルへの注目の高まり、集学的医療サービスへのアクセスの改善などに起因しています。予測期間における主要動向としては、個別化治療の採用の増加、神経障害症状のリアルタイムモニタリングと治療のためのウェアラブルデバイスの使用の増加、遠隔診察とフォローアップのための遠隔医療サービスの拡大、特定の神経障害性疼痛の経路とメカニズムに対処する標的治療の開発、再生医療技術の進歩、認知行動療法、マインドフルネスによる介入のためのデジタル治療プラットフォームの統合、末梢神経障害の早期発見とモニタリングのための診断ツールの技術進歩などが挙げられます。

糖尿病の有病率の増加は、今後数年間の末梢神経障害市場の成長を促進すると予想されます。糖尿病は、体内でインスリンを生成したり適切に使用したりすることができないために血糖値が上昇する慢性疾患です。糖尿病患者の増加は、肥満率の増加、座りがちなライフスタイル、高齢化などの要因によるところが大きいです。糖尿病は、高血糖の状態が長く続くことで神経が障害され、四肢の痛み、しびれ、麻痺などの症状を引き起こす末梢神経障害につながる可能性があります。この合併症の予防や進行を遅らせるためには、適切な血糖管理が不可欠です。例えば、2023年4月、英国を拠点とする糖尿病慈善団体である英国糖尿病協会（The British Diabetic Association）は、英国で430万人が糖尿病と診断され、2020～2021～2021～22年にかけて14万8,951件増加すると報告しました。さらに、英国では240万人以上が2型糖尿病を発症するリスクが高いです。その結果、糖尿病有病率の上昇が末梢神経障害市場の成長を促進しています。

末梢神経障害市場の主要企業は、糖尿病の診断と管理を強化するために、ポイントオブケア機器を含む先進的なソリューションの開発に注力しています。ポイントオブケア末梢神経障害定量スクリーニング検査は、特に糖尿病患者の神経損傷を迅速に検出するために使用される診断ツールです。例えば、米国の医療機器メーカーであるニューロメトリックス社は、2023年1月にDPNCheck 2.0を発表しました。このポイントオブケア機器は、神経伝導技術を用いて末梢神経機能を定量的に評価し、糖尿病末梢神経障害（DPN）などの疾患の迅速なスクリーニングを記載しています。モノフィラメント検査や音叉検査といった従来型方法を大きく前進させ、より効率的で正確な診断能力を記載しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の末梢神経障害 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の末梢神経障害市場：成長率分析
• 世界の末梢神経障害市場の実績：規模と成長、2019～2024年
• 世界の末梢神経障害市場の予測：規模と成長、2024～2029年、2034年
• 世界の末梢神経障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の末梢神経障害市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法誘発性
• 糖尿病
• ヒト免疫不全ウイルス（HIV）または後天性免疫不全症候群（AIDS）
• 特発性
• 世界の末梢神経障害市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 血液検査
• 生検
• 画像診断
• その他
• 世界の末梢神経障害市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品
• 抗うつ薬
• 抗てんかん薬
• 鎮痛剤
• 局所治療
• 治療法
• 神経刺激
• 血漿交換
• 理学療法
• その他
• 世界の末梢神経障害市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来センター
• 世界の末梢神経障害市場、化学療法誘発性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• タキサン誘発性末梢神経障害
• プラチナ製剤誘発性神経障害
• その他の化学療法誘発性神経障害
• 世界の末梢神経障害市場、糖尿病のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 1型糖尿病誘発性末梢神経障害
• 2型糖尿病誘発性末梢神経障害
• 世界の末梢神経障害市場、ヒト免疫不全ウイルス（HIV）または後天性免疫不全症候群（AIDS）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• HIV関連末梢神経障害
• エイズ関連末梢神経障害
• 世界の末梢神経障害市場、特発性疾患のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性特発性神経障害
• 慢性特発性神経障害

第7章 地域別・国別分析

• 世界の末梢神経障害市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の末梢神経障害市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 末梢神経障害市場：競合情勢
• 末梢神経障害市場：企業プロファイル
  • Pfizer Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Bristol Myers Squibb Co
  • AstraZeneca Plc

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Eli Lilly and Co.
• Asahi Kasei Corporation
• Daiichi Sankyo Co. Ltd.
• Sun Pharmaceutical Industries Ltd
• Aurobindo Pharma
• Cadila Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories
• Cipla Ltd.
• Apotex Inc
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Grunenthal GmbH
• ACI Limited
• Lexicon Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 末梢神経障害市場、2029年：新たな機会を提供する国
• 末梢神経障害市場、2029年：新たな機会を提供するセグメント
• 末梢神経障害市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Peripheral neuropathy is a condition where the peripheral nerves, responsible for transmitting signals between the central nervous system (brain and spinal cord) and the rest of the body, suffer damage or dysfunction. Symptoms typically manifest as numbness, tingling, weakness, and pain, commonly affecting the hands and feet.

The primary types of peripheral neuropathy include chemotherapy-induced, diabetic, HIV/AIDS-associated, and idiopathic. Chemotherapy-induced neuropathy refers to complications resulting from chemotherapy treatment. Diagnosis involves blood tests, biopsies, imaging, and other methods, while treatment options encompass medications, antidepressants, anti-seizure drugs, pain relievers, topical treatments, therapies, nerve stimulation, plasma exchange, physical therapy, and more. End users of these treatments include hospitals, clinics, and ambulatory centers.

The peripheral neuropathy research report is one of a series of new reports from The Business Research Company that provides peripheral neuropathy market statistics, including the peripheral neuropathy industry's global market size, regional shares, competitors with a peripheral neuropathy market share, detailed peripheral neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral neuropathy industry. This peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peripheral neuropathy market size has grown rapidly in recent years. It will grow from $4.09 billion in 2024 to $4.62 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to the increased prevalence of chronic diseases like diabetes, growth in awareness about neuropathic pain management, rise in geriatric population globally, expansion of healthcare infrastructure, availability of specialized treatment centers, government initiatives aimed at improved neurological healthcare services, growing adoption of novel treatment options.

The peripheral neuropathy market size is expected to see rapid growth in the next few years. It will grow to $7.52 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the continued rise in the prevalence of chronic diseases, particularly diabetes and cancer, advancements in pharmacological therapies targeting neuropathic pain pathways, increased investment in research and, development for innovative treatment modalities, integration of digital health solutions for remote monitoring and personalized management of neuropathic symptoms, heightened focus on patient-centric care models, improved access to multidisciplinary healthcare services. Major trends in the forecast period include increasing adoption of personalized treatment, growing use of wearable devices for real-time monitoring of neuropathic symptoms and treatment, expansion of telemedicine services for remote consultations and follow-ups, development of targeted therapies addressing specific neuropathic pain pathways and mechanisms, advancements in regenerative medicine techniques, integration of digital therapeutics platforms for cognitive behavioral therapy, mindfulness-based interventions, technological advancements in diagnostic tools for early detection and monitoring of peripheral neuropathy.

The increasing prevalence of diabetes is expected to drive the growth of the peripheral neuropathy market in the coming years. Diabetes is a chronic condition marked by elevated blood glucose levels due to the body's inability to produce or properly use insulin. The rise in diabetes cases is largely attributed to factors such as increasing obesity rates, sedentary lifestyles, and an aging population. Diabetes can lead to peripheral neuropathy, a condition caused by nerve damage from prolonged high blood sugar, resulting in symptoms like pain, tingling, and numbness in the extremities. Proper blood sugar management is essential to prevent or slow the progression of this complication. For example, in April 2023, The British Diabetic Association, a UK-based diabetes charity, reported that 4.3 million individuals in the UK were diagnosed with diabetes, with an increase of 148,951 cases from 2020-21 to 2021-22. Additionally, more than 2.4 million people in the UK are at high risk of developing type 2 diabetes. Consequently, the rising prevalence of diabetes is fueling the growth of the peripheral neuropathy market.

Leading companies in the peripheral neuropathy market are focusing on developing advanced solutions, including point-of-care devices, to enhance the diagnosis and management of the condition. Point-of-care peripheral neuropathy quantitative screening tests are diagnostic tools used to quickly detect nerve damage, particularly in individuals with diabetes. For example, NeuroMetrix Inc., a US-based medical device manufacturer, introduced the DPNCheck 2.0 in January 2023. This point-of-care device uses nerve conduction technology to assess peripheral nerve function quantitatively, offering rapid screening for conditions such as diabetic peripheral neuropathy (DPN). It represents a significant advancement over traditional methods such as monofilament and tuning fork tests, providing more efficient and accurate diagnostic capabilities.

In January 2022, Withings, a France-based connected health technology company, acquired Impeto Medical for an undisclosed sum. This acquisition includes Impeto's proprietary SUDOSCAN technology, which assesses the response of sweat glands in the palms and soles to detect potential nerve damage and monitor peripheral neuropathies. Impeto Medical is a France-based medical device manufacturer specializing in health status detection devices.

Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Asahi Kasei Corporation, Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, ACI Limited, Lexicon Pharmaceuticals, Solasia Pharma KK, Helixmith Co. Ltd., PledPharma AB

North America was the largest region in the peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral neuropathy market consists of revenues earned by entities by providing services such as neurological evaluation, pain management, physical therapy, occupational therapy, podiatry services, orthopedic support, nutritional counseling, psychological support, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral neuropathy market also includes sales of pain relief creams, orthopedic shoes, compression socks, tens devices, foot care kits, braces and supports, nutritional supplements, mobility aids, and assistive devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peripheral Neuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peripheral neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peripheral neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peripheral neuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Chemotherapy-Induced; Diabetic; Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated; Idiopathic
• 2) By Diagnosis: Blood Test; Biopsy; Imaging; Other Diagnosis
• 3) By Treatment: Medications; Antidepressants; Anti-Seizure Medication; Pain Reliever; Topical Treatment; Therapies; Nerve Stimulation; Plasma Exchange; Physical Therapy; Other Treatments
• 4) By End-User: Hospitals; Clinics; Ambulatory Centers
• Subsegments:
• 1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy; Platinum-Based Drug-Induced Neuropathy; Other Chemotherapy-Induced Neuropathies
• 2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy; Type 2 Diabetes-Induced Peripheral Neuropathy
• 3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy; AIDS-Related Peripheral Neuropathy
• 4) By Idiopathic: Acute Idiopathic Neuropathy; Chronic Idiopathic Neuropathy
• Companies Mentioned: Pfizer Inc.; Merck and Co. Inc.; Novartis AG; Bristol Myers Squibb Co; AstraZeneca Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peripheral Neuropathy Market Characteristics

3. Peripheral Neuropathy Market Trends And Strategies

4. Peripheral Neuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Peripheral Neuropathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Peripheral Neuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Peripheral Neuropathy Market Growth Rate Analysis
• 5.4. Global Peripheral Neuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Peripheral Neuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Peripheral Neuropathy Total Addressable Market (TAM)

6. Peripheral Neuropathy Market Segmentation

• 6.1. Global Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy-Induced
• Diabetic
• Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated
• Idiopathic
• 6.2. Global Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Test
• Biopsy
• Imaging
• Other Diagnosis
• 6.3. Global Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Antidepressants
• Anti-Seizure Medication
• Pain Reliever
• Topical Treatment
• Therapies
• Nerve Stimulation
• Plasma Exchange
• Physical Therapy
• Other Treatments
• 6.4. Global Peripheral Neuropathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Centres
• 6.5. Global Peripheral Neuropathy Market, Sub-Segmentation Of Chemotherapy-Induced, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Taxane-Induced Peripheral Neuropathy
• Platinum-Based Drug-Induced Neuropathy
• Other Chemotherapy-Induced Neuropathies
• 6.6. Global Peripheral Neuropathy Market, Sub-Segmentation Of Diabetic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes-Induced Peripheral Neuropathy
• Type 2 Diabetes-Induced Peripheral Neuropathy
• 6.7. Global Peripheral Neuropathy Market, Sub-Segmentation Of Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HIV-Associated Peripheral Neuropathy
• AIDS-Related Peripheral Neuropathy
• 6.8. Global Peripheral Neuropathy Market, Sub-Segmentation Of Idiopathic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Idiopathic Neuropathy
• Chronic Idiopathic Neuropathy

7. Peripheral Neuropathy Market Regional And Country Analysis

• 7.1. Global Peripheral Neuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Peripheral Neuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peripheral Neuropathy Market

• 8.1. Asia-Pacific Peripheral Neuropathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peripheral Neuropathy Market

• 9.1. China Peripheral Neuropathy Market Overview
• 9.2. China Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peripheral Neuropathy Market

• 10.1. India Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peripheral Neuropathy Market

• 11.1. Japan Peripheral Neuropathy Market Overview
• 11.2. Japan Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peripheral Neuropathy Market

• 12.1. Australia Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peripheral Neuropathy Market

• 13.1. Indonesia Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peripheral Neuropathy Market

• 14.1. South Korea Peripheral Neuropathy Market Overview
• 14.2. South Korea Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peripheral Neuropathy Market

• 15.1. Western Europe Peripheral Neuropathy Market Overview
• 15.2. Western Europe Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peripheral Neuropathy Market

• 16.1. UK Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peripheral Neuropathy Market

• 17.1. Germany Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peripheral Neuropathy Market

• 18.1. France Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peripheral Neuropathy Market

• 19.1. Italy Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peripheral Neuropathy Market

• 20.1. Spain Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peripheral Neuropathy Market

• 21.1. Eastern Europe Peripheral Neuropathy Market Overview
• 21.2. Eastern Europe Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peripheral Neuropathy Market

• 22.1. Russia Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peripheral Neuropathy Market

• 23.1. North America Peripheral Neuropathy Market Overview
• 23.2. North America Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peripheral Neuropathy Market

• 24.1. USA Peripheral Neuropathy Market Overview
• 24.2. USA Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peripheral Neuropathy Market

• 25.1. Canada Peripheral Neuropathy Market Overview
• 25.2. Canada Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peripheral Neuropathy Market

• 26.1. South America Peripheral Neuropathy Market Overview
• 26.2. South America Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peripheral Neuropathy Market

• 27.1. Brazil Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peripheral Neuropathy Market

• 28.1. Middle East Peripheral Neuropathy Market Overview
• 28.2. Middle East Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peripheral Neuropathy Market

• 29.1. Africa Peripheral Neuropathy Market Overview
• 29.2. Africa Peripheral Neuropathy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Peripheral Neuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peripheral Neuropathy Market Competitive Landscape And Company Profiles

• 30.1. Peripheral Neuropathy Market Competitive Landscape
• 30.2. Peripheral Neuropathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol Myers Squibb Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Peripheral Neuropathy Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Eli Lilly and Co.
• 31.3. Asahi Kasei Corporation
• 31.4. Daiichi Sankyo Co. Ltd.
• 31.5. Sun Pharmaceutical Industries Ltd
• 31.6. Aurobindo Pharma
• 31.7. Cadila Pharmaceuticals Ltd.
• 31.8. Dr. Reddy's Laboratories
• 31.9. Cipla Ltd.
• 31.10. Apotex Inc
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Lupin Limited
• 31.13. Grunenthal GmbH
• 31.14. ACI Limited
• 31.15. Lexicon Pharmaceuticals

32. Global Peripheral Neuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peripheral Neuropathy Market

34. Recent Developments In The Peripheral Neuropathy Market

35. Peripheral Neuropathy Market High Potential Countries, Segments and Strategies

• 35.1 Peripheral Neuropathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Peripheral Neuropathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Peripheral Neuropathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer